SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Neuroguy who wrote (328)1/22/2000 6:55:00 PM
From: Mark L.  Read Replies (1) of 427
 
A dumb question - for those stocks with a ratio over 1.0, does this represent inaccuracies in calculating the float, a high level of naked shorts, or some other issue?

Not a dumb question at all. The answer is that sometimes non-float shares are hypothecated, and thus are available for shorting. For example, let's say that the CEO of Biogenemedtech has 1 million shares of his $25 stock. He wants to build a $2,000,000 house, but has only a $300,000 salary. The bank won't give him a loan without additional collateral. The only additional asset the CEO has is his Biogenemedtech stock, which the bank accepts as collateral (along with an understanding about registration and lockup issues, if necessary). The bank then makes a few extra bucks lending out that stock to short sellers.

Obviously, it's also possible, as you suggested, that the float is miscalculated (a common error) or that there are a lot of naked shorts (not as common as you might think).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext